早期应用英夫利昔单抗治疗克罗恩病的临床优势探讨  

The Advantages of Early Application of Infliximab to Crohn′s Disease Treatment

作　　者：黄频[1] 余飞龙[1] 李丽[2] 

机构地区：[1]浙江杭州市萧山区第一人民医院,消化内科,杭州311201 [2]浙江大学附属第一医院,消化内科,杭州310003

出　　处：《中国药学杂志》2012年第8期642-644,共3页Chinese Pharmaceutical Journal

摘　　要：目的探讨观察早期使用英夫利昔单抗治疗克罗恩病(crohn's disease,CD)的临床优势及安全性。方法收集48例克罗恩病患者,随机分为早期英夫利昔单抗组(ATI组)与硫唑嘌呤组(AZA组),每组各24例,英夫利昔单抗组患者早期14周应用英夫利昔单抗治疗,后期以硫唑嘌呤维持治疗,而硫唑嘌呤组单用硫唑嘌呤治疗,通过50周的治疗,观察比较两组患者的临床有效率,治疗有效时间,黏膜修复情况及不良反应和并发症。结果治疗50周后,英夫利昔单抗组临床有效率91.67%,明显优于硫唑嘌呤组66.67%(P<0.05);英夫利昔单抗组近期平均治愈时间明显短于硫唑嘌呤组(P<0.05);且英夫利昔单抗组黏膜愈合率25.00%,明显高于硫唑嘌呤组4.17%(P<0.05);两组不良反应无差异,并发症发生率英夫利昔单抗组16.66%,明显低于硫唑嘌呤组组的37.50%(P<0.05)。结论早期应用英夫利昔单抗,后以硫唑嘌呤维持治疗,能在更短的时间内,更好的达到临床有效且更多的黏膜愈合,安全,有效,临床值得推广应用。OBJECTIVE To investigate the clinical efficacy of early application of infliximab to Crohn′s disease treatment.METHODS Forty-eight patients with Crohn′s disease were randomly divided into ATI group and AZA group with 24 patients in each group.The patients in ATI group were treated with infliximab in the first 14 weeks while the patients in AZA group only used azathioprine.Both groups were followed up for 50 weeks.The clinical efficacy,adverse reactions,treatment effective time and recurrences were compared between the two groups.RESULTS The clinical effective rate in the ATI group was 91.67%,significantly higher than that in AZA group（66.67%,P0.05）;the average time of cure for the ATI group was shorter than the control group（P0.05）;the mucosal healing rates was 25.00%,significantly higher than the AZA group（4.17%,P0.05）;the recurrence rate in the ATI group was 16.66%,lower than the AZA group（37.50 %,P0.05）.CONCLUSION The method has good efficacy for Crohn′s disease.It can significantly improve the clinical efficacy,reduce adverse reactions,complications and recurrence rate,and should be widely used in clinic.

关 键 词：英夫利昔单抗 硫唑嘌呤 克罗恩病 

分 类 号：R965[医药卫生—药理学]